Abstract 1243P
Background
Ocular surface squamous neoplasia (OSSN) is a common eye surface neoplastic disease ranging from non-invasive conjunctival intraepithelial neoplasia (CIN) to invasive forms of squamous cell carcinoma (SCC) that accounts for approximately 10% of ocular surface lesions. Early detection of OSSN is crucial for effective treatment. However, clinical symptoms of OSSN vary, which can result in delayed or inappropriate diagnosis without appropriate diagnostic methods. Currently, the diagnosis of OSSN relies on clinical suspicion confirmed by impression cytology or biopsy, which are invasive and may not detect small lesions. This study aims to introduce an artificial intelligence data analysis framework to empower a newly designed autofluorescence hyperspectral imaging technology developed in our group for OSSN detection.
Methods
We recruited 20 patients who had previously been diagnosed with OSSN. Biopsy specimens were collected from the patients and reprocessed without staining to obtain autofluorescence microscopy images using 25 spectral channels, each with a distinctive excitation-emission wavelength. The spectral images were pre-processed to remove unwanted random noise and then spectral features were extracted from the epithelial section of tissue images. Further, the spectral features were used to form an artificial feature image patch to train a convolutional neural network for image classification.
Results
The technique was evaluated against pathological assessment, and results showed the multispectral analysis was able to detect OSSN in all tested patients (P-value < 0.05). The trained classifier on OSSN and normal sections was found to have great performance (AUC > 83%). The maps produced by the analysis were in close agreement with margins observed in H&E sections. The fully automated diagnostic method based on AI methodology produced maps of the neoplastic-non neoplastic interface that could be generated in quasi-real time and used for intraoperative assessment.
Conclusions
The study demonstrated the feasibility of using AI empowered hyperspectral autofluorescence imaging to detect OSSN and the potential for the technique to be used as a diagnostic tool in future clinical applications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cancer Institute NSW.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1219P - Artificial intelligence-based breast cancer detection facilitates automated prognosis marker assessment using multiplex fluorescence immunohistochemistry
Presenter: Tim Mandelkow
Session: Poster session 14
1220P - Comprehensive diagnose of programmed death-ligand 1 from two-dimensional to three-dimensional in breast cancer with computer-aided artificial intelligence system
Presenter: Yi-Hsuan Lee
Session: Poster session 14
1221P - The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors
Presenter: Lorena Incorvaia
Session: Poster session 14
1222P - Detection of androgen-receptor splice variant 7 messenger RNA in circulating tumor cells of prostate cancer by in vitro assay
Presenter: Hoin Kang
Session: Poster session 14
1223P - Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study
Presenter: Alberto Ranghiero
Session: Poster session 14
1224P - Detection of circulating tumor DNA (ctDNA) in untreated patients (pts) with cancer: Implications for early cancer detection (ECD)
Presenter: Yoshiaki Nakamura
Session: Poster session 14
1225P - Combining ctDNA and tissue-based-genomic profiling in advanced cancer: A real-world evidence prospective study in non-Western patients treated at Gustave Roussy cancer campus
Presenter: Tony Ibrahim
Session: Poster session 14
1226P - Multi-site validation of a deep learning solution for HER2 profiling of breast cancer from H&E-stained pathology slides
Presenter: Salim Arslan
Session: Poster session 14
1227P - Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer
Presenter: Magdalena Staniszewska
Session: Poster session 14
1228P - A circulating tumor cell (CTC) based assay for diagnostic immunocytochemistry profiling of lung cancer
Presenter: Nitesh Rohatgi
Session: Poster session 14